Gwen Melincoff
Director
Ms. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management and project management.
Ms. Melincoff currently sits on the board of directors of Protalix Biotherapeutics and Gain Therapeutics. She previously served on the board at Collegium Pharmaceutical, Soleno Therapeutics, Photocure ASA and Tobira Therapeutics.
She served as Vice President of Business Development at BTG International Inc. a UK- specialist healthcare company from 2014-2016. Prior to that Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals from 2004-2013. Additionally, she led the Strategic Investment Group (SIG), Shire’s $50MM corporate venture fund which was started in 2010. She served as a board member/board observer at DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciences, Naurex Inc. (acquired by Allergan) and Enterome. During her tenure, she was involved in numerous licenses, product divestments, co-promotion and collaboration agreements, and mergers and acquisitions. She was responsible for the collaboration with New River Pharmaceuticals that led to the $2.6 billion acquisition of the company. Ms. Melincoff was named a “Top Women in Biotech 2013” by Fierce Biotech as well as being named to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013.
Prior to joining Shire, Ms. Melincoff was Vice President of Business Development at Adolor Corporation, a biopharmaceutical company focused on the development of pain management products that was acquired by Cubist Pharmaceuticals and then Merck.
Ms. Melincoff worked for Eastman Kodak for over ten years in a number of their health care companies, including Eastman Pharmaceuticals which acquired Sterling Drug. She was the Director of Business Development at NanoSystems, a spin-out from Kodak that specialized in nanotechnology drug delivery that was acquired by Elan.
Ms. Melincoff has a B.S in Biology, a Master’s of Science in Management, and has attained the designation of the Certified Licensing Professional (CLP™).
